Motexafin lutetium
Alternative Names: Antrin®; FP FP1; Lu-Tex; Lu-Tex/OPTRIN; Lutetium texaphyrin; Lutrin®; Optrin™; PCI 0123Latest Information Update: 24 Oct 2021
At a glance
- Originator Pharmacyclics
- Class Antineoplastics; Oxidants; Texaphyrins
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Age-related macular degeneration; Atherosclerosis; Breast cancer; Cervical intraepithelial neoplasia; Coronary artery restenosis; Peripheral arterial disorders; Prostate cancer; Vascular restenosis
Most Recent Events
- 28 Mar 2006 Motexafin lutetium is available for licensing worldwide (http://www.pharmacyclics.com)
- 15 Nov 2004 Data presented at the American Heart Association Scientific Sessions (AHA-2004) have been added to the Ischaemic Heart Disease pharmacodynamics section
- 12 Oct 2004 Data presented at the 16th Annual Transcatheter Cardiovascular Therapeutics conference (TCT-2004) have been added to the Ischaemic Heart Disease therapeutic trials section